Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from the transition to managing Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% in 2025 from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million in 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss for the year would have been approximately $5.6 million when excluding one-time legal expenses [10][11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88% in 2025, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and new distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on scaling current initiatives and maintaining resource allocation discipline while searching for a new CEO [5] - The company aims to accelerate growth in e-commerce, municipal adoption, and technology validation while managing operating expenses carefully [11] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for growth in 2026, aiming for higher revenue growth rates than in 2025 [13] - The company is focused on maintaining financial discipline while investing in areas with traction, such as e-commerce and municipal markets [11] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company ended 2025 with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management indicated that growth could be higher, aiming to accelerate growth in profitable areas [13] Question: What will contribute to 2026 revenues? - Revenue will come from a mix of e-commerce, municipal orders, and international expansion [14][15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company does not expect recurring legal costs related to this issue [22][23] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring regarding product registration [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation is expected to be equity-based and aligned with long-term shareholder value [56] Question: How is the agricultural sector performing? - The agricultural sector is performing well, with expansions in various areas including almond groves and poultry [33] Question: Will the company expand its sales team? - Yes, the company plans to expand its sales team to maximize B2B sales efforts [60]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from the transition to managing Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million for 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss would have been approximately $5.6 million when excluding one-time legal expenses [10][11] - Adjusted EBITDA loss improved to $5.3 million compared to $5.8 million in 2024 [11] - The company ended the year with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88%, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on scaling current initiatives and maintaining resource allocation discipline [5] - The board is engaged in finding a new CEO to help scale the business and build on progress made [5] - The company aims to maintain financial discipline while investing in areas with traction, including e-commerce and municipal adoption [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating growth in 2026, particularly in e-commerce and municipal markets [13][15] - The company is focused on maximizing growth while ensuring profitability [13] - Management is confident in the potential for improvement in financial performance and is preparing for increased demand [45][46] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company is preparing for a significant year ahead, with expectations for growth in various markets [72] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management aims for higher growth rates, particularly in areas where they can maximize profitability [13] Question: What will contribute to 2026 revenues? - Revenue will come from a mix of e-commerce, municipal orders, and international expansion [15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company considers it a past issue [22] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation will be equity-based and aligned with long-term shareholder value [56] Question: How is the agricultural sector performing? - The agricultural sector is expanding, with successes noted in almond groves and poultry [33] Question: Will the company expand its sales team? - Yes, the company plans to expand its sales team to maximize B2B sales efforts [60]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from transitioning to direct management of Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million for 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss for the year would have been approximately $5.6 million when excluding one-time legal expenses [10][11] - Adjusted EBITDA loss improved to $5.3 million compared to $5.8 million in 2024 [11] - The company ended the year with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88%, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [7][8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and new distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on delivering current initiatives, scaling areas with traction, and maintaining resource allocation discipline [5] - The board is engaged in finding a new CEO to help scale the business and build on progress made [4][5] - The company aims to maintain financial discipline while investing in areas with traction, including e-commerce expansion and municipal adoption [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating growth in 2026, aiming for higher growth rates than 2025 [13] - The company is focused on a mixture of revenue contributors, including e-commerce, municipal orders, and international expansion [15][17] - Management is confident in the potential for improvement in profitability and revenue growth [45] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company is preparing for a significant year ahead, with expectations for growth in various markets [74] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management indicated that growth could be higher, aiming to accelerate growth in profitable areas [13] Question: What will contribute to 2026 revenues? - A mixture of e-commerce, municipal orders, and international expansion is expected to drive revenue [15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company considers it a past issue [22] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation is expected to be equity-based [56] Question: How is the agricultural sector performing? - The agricultural sector is performing well, with expansions in various areas including almond groves and poultry [33] Question: What municipalities besides New York City are evaluating Evolve? - Baltimore and Chicago are mentioned, with ongoing assessments in various neighborhoods [32] Question: Will the sales team be expanded? - Yes, the company plans to expand the sales team to maximize B2B sales efforts [61]

Core Insights - SenesTech, Inc. has launched a pilot program in Swampscott, Massachusetts, utilizing Evolve® Rat Birth Control to manage rat populations humanely without harsh chemicals [1][4] - The initiative aims to provide a sustainable solution to pest control, focusing on prevention rather than short-term elimination [4] Company Overview - SenesTech specializes in fertility control for pest management, having developed products like ContraPest and Evolve Rat, which are designed to be humane, effective, and sustainable [5] - The company’s mission is to improve public health by managing animal pest populations through innovative fertility control methods [5] Pilot Program Details - The pilot program is a collaboration with Speak Up for Animals and local advocate Debora Norman, aiming to protect public health while minimizing risks to children, pets, and wildlife [2] - Evolve Rat works by controlling rat reproduction, addressing the root cause of infestations, and has shown success in various settings across the country [3] Community Impact - Swampscott is one of the first communities in Massachusetts to implement this innovative pest control method, reflecting a commitment to safer and more responsible rodent management [4] - The pilot will be monitored closely, with potential expansion to additional neighborhoods in 2026 if successful [4]

Summary of SenesTech Investor Conference Company Overview - **Company Name**: SenesTech - **Ticker Symbol**: SNES - **Industry**: Rodent Control Solutions - **Key Product**: Evolve (rodent birth control product) Core Industry Insights - Rodents are a significant public health issue, causing over **$27 billion** in infrastructure damage annually in the U.S. alone and destroying nearly **20%** of the world's food supply [2][3] - The global market for rodenticides is approximately **$4.5 billion**, with the U.S. market spending over **$1 billion** annually [11][23] - Traditional rodenticides are facing increasing resistance and regulatory restrictions, leading to a demand for humane and sustainable alternatives [10][24] Key Product Features and Innovations - SenesTech's products are the only registered rodent birth control solutions available commercially, focusing on suppressing rodent reproduction rather than just extermination [2][5] - The product **Evolve** has become the top-selling item, significantly changing the company's trajectory and expanding market reach [7][8] - Evolve has shown to reduce rat populations by **90%** when integrated into pest management programs [6][8] Financial Performance - **2024 Revenue Growth**: Up **56%**, driven by a **107%** increase in e-commerce sales due to Evolve [8][25] - **Gross Margin**: Improved to **65%** in Q2 2025, up from **54%** in the previous year [18][25] - **Revenue Breakdown**: E-commerce accounted for **56%** of Q2 sales, with a **78%** increase year-over-year [16][17] Market Strategy and Expansion - SenesTech is targeting multiple verticals: consumer, cities and governments, pest management, agribusiness, facilities management, and industrial applications [11][24] - The company has established a multi-channel distribution strategy, with **60%** of revenue coming from e-commerce platforms like Amazon and Walmart [11][12] - Recent municipal deployments in cities like Chicago and New York City are expected to drive future growth [14][15] Regulatory and Competitive Advantages - SenesTech has a regulatory head start with **EPA** approvals and a **FIFRA 25(b)** exemption, which competitors will find challenging to replicate [9][10] - The company holds proprietary know-how and has conducted extensive efficacy studies, establishing a strong competitive position in the market [9][10] Future Outlook - The company aims to achieve profitability with a break-even point estimated at **$6.5 to $7 million** in annual revenues [20][25] - Continued focus on operational efficiencies and growth in e-commerce, municipal, and international markets is expected to drive revenue [23][24] Additional Insights - The introduction of Evolve has allowed SenesTech to expand its market to include mice, enhancing growth opportunities [23] - The company has reduced cash burn by **$2 million** annually and is prioritizing investments in e-commerce and government sales [24][25]

Summary of SenesTech (SNES) Conference Call - August 19, 2025 Company Overview - **Company**: SenesTech - **Ticker Symbol**: SNES - **Industry**: Biotech and Life Sciences, specifically pest control - **Core Product**: Rodent birth control solutions disrupting the rodenticide market, focusing on sustainable pest management [3][4] Key Points and Arguments Industry Context - **Rodent Problem**: Rodents cause over $27 billion in infrastructure damage annually in the U.S. and destroy nearly 20% of the world's food supply [4][5] - **Current Solutions**: Existing rodenticides are largely poisons that are ineffective and harmful, leading to resistance and bans in various jurisdictions [6][7] Product Differentiation - **Unique Approach**: SenesTech focuses on suppressing rodent reproduction rather than increasing mortality rates, with products that are humane and do not harm non-target species [11][12] - **Evolve Product**: Launched as a solid bait, it has an 18-month shelf life and is designed for both professional and DIY use, significantly expanding market reach [16][17] Market Position and Competitive Advantage - **Regulatory Head Start**: SenesTech has a FIFRA 25B minimum risk exemption and approvals in 48 states, giving it a significant advantage over competitors [18][19] - **Intellectual Property**: The company holds patents and trade secrets that protect its unique formulations and efficacy studies [20][21] Market Opportunities - **Market Size**: The U.S. rodenticide market is approximately $1 billion, with a global market of $4.5 billion [26][63] - **Target Verticals**: Key markets include consumers, cities and governments, pest management, agribusiness, facilities management, and food production [26][27] Sales and Distribution Strategy - **E-commerce Growth**: E-commerce accounts for over 60% of revenue, with a 78% increase year-over-year, driven by the popularity of Evolve [31][32] - **Municipal Deployments**: Significant traction in cities like Chicago and New York, with successful pilot programs leading to reorders and increased consumer adoption [36][38] Financial Performance - **Revenue Growth**: Total revenue is approximately $2 million annually, with Evolve sales increasing by 94%, making up 83% of second-quarter sales [51][52] - **Gross Margins**: Improved to 65.4% in Q2, driven by the profitability of the Evolve product [55] - **Cash Position**: The company ended the quarter with $6.1 million in cash, with a pro forma cash position of about $12 million, providing a runway into 2027 [60][61] Future Outlook - **Regulatory Tailwinds**: Increasing bans on traditional rodenticides and a push for humane alternatives create a favorable environment for SenesTech's products [63][64] - **Growth Strategy**: Focus on e-commerce, international markets, and government sales, with expectations for strong revenue growth and margin expansion [66][67] Additional Important Points - **International Expansion**: Successful pilot programs in markets like Hong Kong and the Netherlands, with potential for significant orders [43][44] - **Brick and Mortar Retail**: Recent agreements with distributors to expand into physical retail, with a nearly 500% increase in brick-and-mortar sales sequentially [46][47] This summary encapsulates the key insights from the SenesTech conference call, highlighting the company's innovative approach to pest control, market opportunities, and financial performance.

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $625,000, representing a 36% increase year-over-year and a 29% sequential increase [19] - EVOLVE sales increased by 94% year-over-year and accounted for 83% of total revenue, while ContraPest sales decreased by approximately 45% [19] - Gross profit margins improved to 65.4%, up from 54.2% in the same quarter last year and 64.5% sequentially [22] Business Line Data and Key Metrics Changes - EVOLVE now constitutes 83% of total quarterly revenue, with gross profit dollars up 64% compared to last year's Q2 [6][22] - E-commerce sales grew by 78% year-over-year and accounted for over 50% of quarterly sales, with Amazon leading the channel [8][20] - Municipal sales saw a 538% increase year-over-year, driven by deployments in cities like Chicago and New York [21] Market Data and Key Metrics Changes - E-commerce sales were up 78% compared to last year and up 18% sequentially, with significant growth in brick-and-mortar retail sales, which increased nearly 500% sequentially [8][21] - International sales included a follow-on order from the Caribbean, with ongoing regulatory approvals in Australia and New Zealand [12][21] Company Strategy and Development Direction - The company is focused on expanding its market presence through the EVOLVE product line, which has opened new verticals and distribution channels [5][16] - Plans are in place to accelerate e-commerce growth and expand into agricultural applications, where significant opportunities exist [32][14] - The company aims to achieve cash flow breakeven at approximately $1,500,000 in quarterly revenue, with expectations for growth in 2026 [25][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth from city and government trials, anticipating increased orders as results from trials prove successful [33] - The company is optimistic about its position in the market, citing a large addressable global market and regulatory tailwinds [28] - Management highlighted the importance of focusing on the EVOLVE product line to maximize market penetration and operational efficiency [49] Other Important Information - The company ended the quarter with $6,100,000 in cash, following successful financing activities [26] - The new manufacturing facility has the capacity to produce approximately $10,000,000 in revenue, with plans for further expansion [34] Q&A Session Summary Question: Should we expect incremental improvements to gross margins in the coming quarters? - Yes, management expects margins to remain consistent and possibly improve [30] Question: Is there room to accelerate e-commerce growth with additional digital marketing spend? - Yes, plans are in place to accelerate growth across all channels [31] Question: Should we expect higher volumes from cities where the product has been launched? - Yes, as trials prove successful, increased orders and revenues are anticipated [33] Question: What is the potential capacity in terms of dollars of the expanded manufacturing facility? - The facility can produce roughly $10,000,000 in revenue with current operations [34] Question: Are you planning to do more capital raises in the future? - No further financings are anticipated in the near future, as the company has sufficient cash to reach cash flow profitability [36] Question: Would a full-scale New York City expansion require a big capital investment? - No significant capital investment is required immediately, but future expansions may need some capital [38] Question: Do you need to hire additional people to meet growth expectations? - Yes, the company is hiring salespeople and expanding its field team to support growth [40] Question: Are there any active trials that have not been announced? - Yes, there are ongoing trials that have not yet been disclosed [42] Question: How long before you are in store with Tractor Supply? - The company hopes to have news on this in the coming months [46] Question: Can you specify how OpEx will be cut? - Cuts have already been made, and there are no specific plans for further reductions at this time [47]

Summary of SenesTech (SNES) 2025 Conference Call Company Overview - **Company**: SenesTech, a biotech and life sciences company focused on rodent control through reproductive management rather than lethal methods [5][6] - **Ticker Symbol**: SNES, traded on NASDAQ [4] Core Product and Market Strategy - **Flagship Product**: Evolve, launched in 2024, is a soft bait designed for rodent fertility control, which has quickly become the top-selling product [12][14] - **Sales Growth**: Evolve sales grew by 40% year-over-year in Q1 2025 [15][37] - **Market Opportunity**: The U.S. rodenticide market is estimated at $1 billion annually, with a global market of $4.5 billion [34] Unique Selling Proposition - **Sustainable Approach**: Focus on controlling the birth rate of rodents rather than relying on poisons, which have social, political, and ecological drawbacks [6][8][30] - **Product Safety**: Evolve is designated as a minimum risk product by the EPA, using cottonseed oil as the active ingredient, making it safer for pets and wildlife [14][16] Distribution Channels - **Six Channel Strategy**: Includes e-commerce, agriculture distributors, pest management distributors, retail (e.g., Ace Hardware), international distributors, and direct sales to large customers [18][19] - **E-commerce Growth**: E-commerce sales increased by over 7%, with a run rate approaching $60,000 to $70,000 per month [20][21] Municipal and International Opportunities - **Municipal Deployments**: Significant projects in Chicago and New York City, with repeat orders indicating product effectiveness [23][24][25] - **International Expansion**: Exclusive distribution agreements signed in 12 countries, with expected approvals in Australia and New Zealand [27][28] Financial Performance - **Revenue Growth**: Record revenue of $1.9 million in 2024, up 56% from the previous year [39] - **Gross Margin Improvement**: Gross margins for Evolve reached 64%, compared to 32% in Q1 of the previous year [40] - **Cost Optimization**: Initiatives to reduce operating costs include pausing new product development and optimizing sales efforts [44] Future Outlook - **Path to Profitability**: Aiming for cash flow breakeven at approximately $1.5 million per quarter, with current revenues around $500,000 per quarter [45][46] - **Market Trends**: Increasing awareness of the need for humane rodent control solutions due to public health concerns and regulatory changes [52][53] Key Takeaways - **Transformative Opportunity**: SenesTech believes it has a paradigm-changing product that addresses long-standing rodent control issues in a sustainable manner [55][56] - **Execution Strategy**: Focus on expanding market presence, improving product offerings, and enhancing operational efficiencies to drive future growth [54][56]

Company Participation - SenesTech, Inc. will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - The webcast presentation is scheduled for 3:30 p.m. ET and will be accessible via the conference home page or directly through a provided link [2] - Management will engage in virtual one-on-one meetings throughout the event, with arrangements available through Lytham Partners [3] Company Overview - SenesTech is focused on improving global health by managing animal pest populations through fertility control solutions [4] - The company developed ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, along with Evolve and Evolve Mouse, which are EPA-designated minimum risk contraceptives for rodents [4] - SenesTech aims to integrate its products into pest management programs to enhance effectiveness and promote humane, safe, and sustainable pest control [4]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $485,000, an increase of 17% from Q1 2024 [17] - EVOLVE revenue grew by 40% and accounted for 79% of total sales, while ContraPest revenue decreased by approximately 40% [17] - Gross margins increased to 64.5% compared to 32.5% in Q1 2024, with gross profit rising by 132% to $313,000 [20][21] Business Line Data and Key Metrics Changes - EVOLVE product line significantly contributed to revenue growth, with e-commerce sales increasing by 107% [10][18] - Municipal sales saw a sevenfold increase compared to the previous year, driven by new deployments in major cities [19] - ContraPest, while deemphasized, still retains a loyal customer base and is expected to continue generating revenue [17] Market Data and Key Metrics Changes - E-commerce accounted for 61% of overall Q1 sales, with Amazon being the predominant channel [18] - International sales were not recognized in Q1 but are anticipated to grow with pending regulatory approvals in various markets [19][12] Company Strategy and Development Direction - The company is focusing on expanding the EVOLVE product line and enhancing operational efficiencies to achieve profitability [15][25] - Strategic initiatives have been implemented to reduce expenses by $2 million annually, which should improve financial performance in upcoming quarters [15][22] - The company aims to penetrate various markets, including agriculture, zoos, and residential applications, to drive future growth [27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for significant growth in municipal applications and other markets [26] - The company is on a pathway to profitability, with a reduced revenue threshold for cash flow breakeven set at $1.5 million quarterly [16][22] - There is a clear focus on executing strategies effectively while maintaining efficiency [25] Other Important Information - The company completed a strategic financing during Q1, raising $1 million and issuing $4 million in short-term warrants [23] - The new larger facility in Phoenix is expected to support increasing demand without significantly raising costs [21] Q&A Session Summary - No questions were asked during the Q&A session, leading to a conclusion of the call [29]